Barclays
PSTX

Barclays’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Barclays’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-104,822
Closed -$1.01M – 5676
2024
Q4 		$1.01M Sell
104,822
-15,642
-13% -$81.6K ﹤0.01% 3376
2024
Q3 		$345K Buy
120,464
+68,688
+133% +$213K ﹤0.01% 3994
2024
Q2 		$151K Sell
51,776
-23,569
-31% -$64.5K ﹤0.01% 3724
2024
Q1 		$240K Sell
75,345
-45,992
-38% -$153K ﹤0.01% 4016
2023
Q4 		$408K Buy
121,337
+75,795
+166% +$195K ﹤0.01% 4006
2023
Q3 		$108K Buy
45,542
+13,174
+41% +$27.6K ﹤0.01% 3574
2023
Q2 		$57K Sell
32,368
-70,177
-68% -$179K ﹤0.01% 3777
2023
Q1 		$316K Buy
102,545
+44,436
+76% +$266K ﹤0.01% 3550
2022
Q4 		$308K Buy
58,109
+26,650
+85% +$122K ﹤0.01% 3612
2022
Q3 		$111K Buy
31,459
+1,858
+6% +$6.14K ﹤0.01% 3507
2022
Q2 		$76K Sell
29,601
-4,498
-13% -$12.5K ﹤0.01% 3884
2022
Q1 		$152K Buy
+34,099
New +$154K ﹤0.01% 3584

Other funds holding PSTX

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Barclays's PSTX Position: Q1 2025 in Review

Barclays sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2025, closing a stake of 104,822 shares — an estimated $1.01M sold.

Barclays first reported a position in PSTX in Q1 2022 and held it in 12 quarters. The position peaked at $1.01M in Q4 2024. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.

  • Barclays reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Barclays sold 104,822 Poseida Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $1.01M.
  • Barclays first reported a position in Poseida Therapeutics, Inc. Common Stock in Q1 2022 and held it in 12 quarters.
  • Barclays's Poseida Therapeutics, Inc. Common Stock position peaked at $1.01M in Q4 2024.
  • 1 fund tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2025.

Based on Barclays's 13F filing for Q1 2025, filed 15 May 2025.